NeuroOne Medical Technologies Corporation reported preliminary unaudited product revenue growth of 163% to a record $9.1 million for the fiscal year ended September 30, 2025, compared to $3.5 million in fiscal 2024. The medical technology company, which focuses on improving surgical care options for patients with neurological disorders, also reported preliminary cash and cash equivalents of $6.6 million as of September 30, 2025. This substantial financial performance underscores the growing market acceptance of the company's innovative neurological treatment technologies.
Chief Executive Officer Dave Rosa attributed the remarkable revenue growth to expanded customer interest and positive outcomes with the company's OneRF Ablation system for patients suffering from seizures associated with epilepsy. Rosa stated the company believes it is well positioned to expand use of the OneRF technology platform, indicating confidence in future growth prospects for the neurological treatment technology. The company's success reflects the significant unmet medical needs in neurological care and the potential for minimally invasive solutions to transform treatment approaches.
NeuroOne is developing and commercializing minimally invasive and high-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from various neurological disorders including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. The company's technologies aim to improve patient outcomes while reducing procedural costs, addressing significant healthcare challenges in neurological care. For more information about the company's technology and business developments, visit https://nmtc1.com.
The company will host a virtual investor webinar to discuss its business operations and recent updates, featuring presentations from both Rosa and Chief Financial Officer Ron McClurg. The webinar will include a financial overview and discussion of recent milestone achievements, followed by a question-and-answer session. Complete financial results for the quarter are expected to be announced in December 2025, with the current preliminary results subject to completion of accounting and interim review procedures. The selected unaudited results represent preliminary financial information that management has prepared in good faith on a consistent basis with prior periods. However, this information should not be viewed as a substitute for full financial statements prepared in accordance with United States generally accepted accounting principles.
